Fatty liver disease with 2 and 3 grading. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Control group: In this group, only periodical tests and fiberscan are performed according to what was said. Both groups are advised to follow their diet. Intervention 2: Intervention g
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: In the form of a randomized blinded clinical trial, patients with fibrotic fatty liver with increased liver enzymes (AST and ALT above 40) aged 20 to 70 years who refer to Taleghani Hospital for treatment are examined in terms of inclusion criteria. The criteria for entering the study include grade 2 and 3 fatty liver with increased liver enzymes confirmed by fibroscan and age 20 to 70 years, which is full consent to participate in the study and complete the treatment and follow-up process.
Exclusion criteria
Exclusion criteria: Patients with diabetes, pregnant and lactating, hyperlipidemia and hypercholesterolemia, taking any medication in the last month, hepatitis, cardiovascular patients, hypertension, hyper and hypothyroid, fibroid and polycystic ovary, hormonal disorders, age under 20 and over 50 years and receiving laser for any other reason are excluded from the study process.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Steatosis grading. Timepoint: Before and 1, 3, 6 months after intervention. Method of measurement: Fibrscan.;Fibrosis grading. Timepoint: Before and 1, 3, 6 months after intervention. Method of measurement: Fibrscan.;Biochemical profile. Timepoint: Before and 1, 3, 6 months after intervention. Method of measurement: Blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Razzaghi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed